• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Zydus Cadila gets final US FDA approval for Propafenone Hydrochloride ER capsules

expresspharmaApril 25, 2021

Tag: FDA , Zydus Cadila , Propafenone

Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules). Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Alembic Pharma gets USFDA final approval for Doxepin Hydrochloride Capsules

Next:Gland Pharma gets US FDA nod for generic Foscarnet Sodium Injection, Single-Dose Bag for Infusion

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Zydus Cadila gets final US FDA approval for Propafenone Hydrochloride ER capsules | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Propafenone HCl

Propafenone HCl
Aciclovir (FDA)

Aciclovir (FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Nabumetone (FDA)

Nabumetone (FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Propafenone Hydrochloride Tabl

Propafenone Hydrochloride Tabl
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service